NCT02094443 - Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Hepatitis CLiver Disease

Interventions

DRUG

Alisporivir

ALV 100 and 200 mg soft gel capsules administered orally

DRUG

Ribavirin

RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Trial Locations (16)

23602

Novartis Investigative Site, Newport News

63110

Novartis Investigative Site, St Louis

69317

Novartis Investigative Site, Lyon

75014

Novartis Investigative Site, Paris

76012

Novartis Investigative Site, Arlington

77030

Novartis Investigative Site, Houston

78215

Novartis Investigative Site, San Antonio

92110

Novartis Investigative Site, Clichy

92114

Novartis Investigative Site, San Diego

92128

Novartis Investigative Site, San Diego

93301

Novartis Investigative Site, Bakersfield

93534

Novartis Investigative Site, Lancaster

94010

Novartis Investigative Site, Créteil

98101

Novartis Investigative Site, Seattle

98104

Novartis Investigative Site, Seattle

06202

Novartis Investigative Site, Nice